Results 221 to 230 of about 16,883 (239)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Clinical Infectious Diseases, 2023
Chien-yu Cheng, Stephen Taylor
exaly  

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Lancet HIV,the, 2020
Simiso Sokhela, Bryony Simmons, Michelle A Moorhouse   +2 more
exaly  

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Lancet, The, 2018
Francesco Castelli, Michael Aboud
exaly  

Dolutegravir

Reactions Weekly
  +5 more sources

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Lancet, The, 2013
Andrey Shuldyakov, Carlos Brites, Jaime F Andrade-Villanueva   +2 more
exaly  

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Lancet, The, 2013
Carlo Torti, Chloe Orkin, Mark Bloch
exaly  

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, Andrea Antinori   +2 more
exaly  

Creation of a long-acting nanoformulated dolutegravir

Nature Communications, 2018
Brady Sillman, Aditya N Bade, Prasanta K Dash   +2 more
exaly  

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Lancet Infectious Diseases, The, 2012
Franco Maggiolo, Benjamin Young
exaly  

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Lancet Infectious Diseases, The, 2019
Richard Kaplan, Fujie Zhang, Ploenchan Chetchotisak   +2 more
exaly